Analyst Ratings For Eiger Biopharmaceuticals (NASDAQ:EIGR) (NASDAQ:EIGR)
Today, Wedbush reiterated its Outperform rating on Eiger Biopharmaceuticals (NASDAQ:EIGR) (NASDAQ:EIGR) with a price target of $34.00.
Some recent analyst ratings include
- 3/22/2018-Wedbush Reiterated Rating of Outperform.
- 3/21/2018-Oppenheimer Reiterated Rating of Buy.
- 1/16/2018-Piper Jaffray Companies Reiterated Rating of Overweight.
- 1/3/2018-Ladenburg Thalmann Financial Services initiated coverage with a Buy rating.
- 10/19/2017-Roth Capital initiated coverage with a Buy rating.
- 7/14/2017-BTIG Research initiated coverage with a Buy rating.
- 5/15/2017-Jefferies Group Reiterated Rating of Buy.
Recent Insider Trading Activity For Eiger Biopharmaceuticals (NASDAQ:EIGR) (NASDAQ:EIGR)
Eiger Biopharmaceuticals (NASDAQ:EIGR) (NASDAQ:EIGR) has insider ownership of 28.80% and institutional ownership of 68.96%.
- On 9/1/2017 Jeffrey S Glenn, Director, bought 15,000 with an average share price of $9.53 per share and the total transaction amounting to $142,950.00.
- On 11/18/2016 Jeffrey S Glenn, Director, bought 15,460 with an average share price of $12.74 per share and the total transaction amounting to $196,960.40.
- On 8/18/2016 James P Shaffer, Insider, bought 3,125 with an average share price of $15.70 per share and the total transaction amounting to $49,062.50.
- On 8/18/2016 Ventures Fund Vi L.P. Vivo, Major Shareholder, bought 187,500 with an average share price of $16.00 per share and the total transaction amounting to $3,000,000.00.
- On 6/22/2016 James H Welch, CFO, bought 2,500 with an average share price of $19.80 per share and the total transaction amounting to $49,500.00.
- On 6/13/2016 James P Shaffer, Insider, bought 1,250 with an average share price of $22.17 per share and the total transaction amounting to $27,712.50.
- On 5/23/2016 James P Shaffer, Insider, bought 1,245 with an average share price of $19.80 per share and the total transaction amounting to $24,651.00.
Recent Trading Activity for Eiger Biopharmaceuticals (NASDAQ:EIGR) (NASDAQ:EIGR)
Shares of Eiger Biopharmaceuticals (NASDAQ:EIGR) closed the previous trading session at 9.48 down -0.02 0.26% with shares trading hands.